D. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00

Medicus Pharma (NASDAQ:MDCX - Get Free Report) had its price target hoisted by equities research analysts at D. Boral Capital from $14.00 to $27.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. D. Boral Capital's price objective would suggest a potential upside of 488.24% from the stock's previous close.

A number of other research analysts also recently commented on the company. D Boral Capital upgraded Medicus Pharma to a "strong-buy" rating in a research note on Monday, April 14th. Maxim Group upped their price target on Medicus Pharma from $10.00 to $20.00 and gave the company a "buy" rating in a report on Thursday.

Medicus Pharma Stock Up 9.8%

NASDAQ:MDCX opened at $4.59 on Monday. The firm's 50 day moving average is $3.65. Medicus Pharma has a 12-month low of $1.80 and a 12-month high of $6.00.

Medicus Pharma (NASDAQ:MDCX - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. Equities analysts expect that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma makes up 1.3% of Interchange Capital Partners LLC's holdings, making the stock its 15th biggest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent SEC filing.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.